Abstract
Background: Reliable biomarkers in patients (pts) with pancreatic cancer (PC) are highly warranted. The aim of this prospective-retrospective biomarker study was to investigate the clinical value of cell-free DNA (cfDNA) in pts with PC.Methods: A total of 377 consecutive pts with histologically confirmed PC and 94 healthy controls were included. Total cfDNA levels were determined by a direct fluorescent assay in EDTA plasma samples obtained before operation (stage I and II) or start of palliative chemotherapy (stage III and IV). Serum CA19-9 (IMMULITE 2000, Siemens), hyaluronic acid (HA) (ELISA, R\amp;D), interleukin-6 (IL-6) (ELISA, R\amp;D) and YKL-40 (ELISA, Quidel) were measured. The main outcome was association of cfDNA with overall survival (OS) for pts with PC. Hazard ratios (HRs) and 95\% confidence intervals (CIs) were estimated by Cox proportional hazards regression.
Originalsprog | Engelsk |
---|---|
Artikelnummer | 715P |
Tidsskrift | Annals of Oncology |
Vol/bind | 29 |
Udgave nummer | suppl_8 |
Sider (fra-til) | vii241-vii242 |
Antal sider | 2 |
ISSN | 0923-7534 |
DOI | |
Status | Udgivet - okt. 2018 |
Begivenhed | ESMO 2018 Congress (European Society for Medical Oncology): Securing access to optimal cancer care - München, Tyskland Varighed: 19 okt. 2018 → 23 okt. 2018 http://www.esmo.org/Conferences/ESMO-2018-Congress |
Konference
Konference | ESMO 2018 Congress (European Society for Medical Oncology) |
---|---|
Land/Område | Tyskland |
By | München |
Periode | 19/10/2018 → 23/10/2018 |
Internetadresse |